Open access peer-reviewed chapter

A Novel Strategy of Dual Inhibition of Distinct Metabolic Features in Osteosarcoma

Written By

Shingo Kishi, Kanya Honoki, Yasuhito Tanaka and Hiroki Kuniyasu

Submitted: 21 August 2018 Reviewed: 20 November 2018 Published: 15 March 2019

DOI: 10.5772/intechopen.82612

From the Edited Volume

Osteosarcoma – Diagnosis, Mechanisms, and Translational Developments

Edited by Matthew Gregory Cable and Robert Lawrence Randall

Chapter metrics overview

1,092 Chapter Downloads

View Full Metrics


Mitochondria are the places for the energy production of the cells, while reactive oxygen species (ROS) are also produced alongside. In recent years, it has been reported that cancer stem cells metabolize predominantly through oxidative phosphorylation (OXPHOS) rather than glycolysis. Targeting OXPHOS achieved by suppression of ATP synthesis through mitochondrial ATP synthase could be a potential therapeutic option against cancer stem cells. Since c-Myc inhibition is considered to lead a metabolic flux to OXPHOS from glycolysis, the combinatory inhibition of both OXPHOS and glycolysis could be a strong candidate for the treatment of malignant tumors. In this chapter, we will discuss about the mitochondria metabolism as the potential therapeutic target in osteosarcoma stem cells, and the synergistic effects of combination of OXPHOS inhibitor with c-Myc inhibitor, which target both OXPHOS-dominant cancer stem cells and glycolysis-dominant non-cancer stem cells, will be discussed.


  • osteosarcoma
  • mitochondria
  • metabolism
  • c-Myc

1. Introduction

Intratumor heterogeneity, which is the basis of tumor evolution, is the fundamental challenge in cancer medicine. Intratumor heterogeneity is considered to be involved in several important aspects in cancer biology such as disease relapse and metastatic behaviors as well as drug resistance. Over the past decades, a small subset of tumor cells, so-called cancer stem cells (CSCs), have been proposed to be a hierarchical organizer of the tumor heterogeneity [1] and play a critical role in tumor relapse, metastasis, drug resistance, and tumor propagation in many cancer types including osteosarcoma (OS) [2, 3, 4, 5, 6]. At the apex of the heterogeneity in the tumor, CSCs possess the capacity of self-renew and tumorigenicity which generate the bulk of tumor with more differentiated progenies [7]. Conventional anticancer therapies target the bulk of heterogeneous tumor mass resulting in tumor shrinkage, but CSCs could trigger the relapse by differentiation into non-stem tumor cells. Thus, targeting CSCs could represent an integral component for developing more effective treatment strategies against cancer.

Now, we have evidences that cancer heterogeneity not only is generated by genetically distinct subclones but is also driven by phenotypic and functional heterogeneity within each subclone [8, 9]. One of the distinct phenotypes of CSCs is their cellular metabolism mechanisms for energy production. Tumor cells reprogram their metabolic machinery to meet their needs during tumor growth known as Warburg effect which shifts their ATP production from via oxidative phosphorylation (OXPHOS) to glycolysis even in the microenvironment with abundant oxygen concentration [10]. Over the past years, the metabolic phenotype of CSCs has been intensely investigated, and it was originally hypothesized that CSCs would reflect the normal tissue hierarchy where multipotent stem cells are fundamentally glycolytic, while differentiated somatic cells rely on OXPHOS [11]. Although the differentiated cells increase their dependency upon the glycolysis during the acquisition of the transformed phenotype, these changes might be cell specific, and some cells might adapt to neoplastic transformation by increasing their dependency on OXPHOS [12]. As a matter of fact, the metabolic phenotype of CSCs are controversial suggesting that it could be a tumor-type- or cell line-dependent manner such as breast and nasopharyngeal CSCs relying on glycolysis [13, 14], while lung, glioblastoma and pancreatic ductal adenocarcinoma CSCs relying on OXSPHOS [15, 16, 17]. In osteosarcoma (OS), a CSC-like cell line, 3AB-OS, exhibited its metabolic dependency on glycolysis compared to the parental MG-63 cells [18]. However, this came from only one cell line chemically treated long time from MG-63 which bore the ras gene mutation unusually found in OS. Controversially, there is the evidence that the transformed mesenchymal stem cells (MSCs), which are supposed to be the sarcoma-initiating cells or sarcoma stem cells, showed the increased OXPHOS and had a capability to switch to glycolysis to adapt to their microenvironments [19]. The discrepancy in these metabolic profiles of CSCs would be due to multifactorial causes. The first possible explanation is the plasticity of these cells in response to the microenvironment and the stages of harvesting in terms of differentiation/dedifferentiation [20]. Another possible cause would be the lack of precise definition of CSCs and their heterogeneity due to the various techniques for CSC isolation [21]. Furthermore, the metabolic status of CSCs can be affected by cross talk between CSCs and cancer-associated stroma in the microenvironment. For instance, OS cells directly increase their mitochondrial biogenesis using this energy-rich metabolite such as lactate that is abundantly provided by MSC as an effect of the altered microenvironmental conditions induced by OS cells, and the lactate produced by MSC promotes the migratory ability of OS cell [22].

Actually, there are several reports indicating that CSCs have augmented utilization of extracellular catabolites such as pyruvate, lactate to support OXPHOS, [23] and mitochondrial metabolism could be a potential target for an effective elimination of CSCs [17]. Previous studies suggested that inhibition of the OXPHOS pathway reduced sphere formation and tumor formation capacity, which demonstrated the vulnerability of CSCs to mitochondria-targeted therapies [24], and several agents such as salinomycin targeting CSCs through inhibition of mitochondrial biogenesis and OXPHOS are currently under investigation for cancer treatment [25].

Here, we will discuss about the mitochondrial metabolism as a potential therapeutic target in osteosarcoma, especially its stem-like cell populations.


2. Myc is a key regulator of cancer cell metabolism

Glucose is one of the major nutrients that mammalian cells utilize to synthesize new organelles as well as to generate high-energy molecules, such as ATP, NADH/NADPH, and FADH. c-Myc played an important role in regulation of glycolysis through its target glucose metabolism genes [26], and those genes directly regulated by c-Myc include glucose transporter GLUT1, hexokinase 2 (HK2), phosphofructokinase (PFKM), and enolase 1 (ENO1) [27, 28]. Myc was also observed to upregulate lactate dehydrogenase A (LDHA) to generate NAD+, which is a cofactor required for the glycolysis particularly by GAPDH [29]. Through the upregulation of these genes, c-Myc contributes directly to the Warburg effect (aerobic glycolysis) and the ability of transformed cells to convert glucose to pyruvate even under adequate oxygen tension. Myc also regulates protein synthesis, ribosome biogenesis, nucleotide biosynthesis, as well as fatty acid and cholesterol metabolism. Cancer cells take advantage of these Myc’s broad reaches to reprogram and augment the most critical processes for survival, particularly metabolism.

In addition to the metabolic reprogramming, c-Myc also contributes to the cell cycle regulation in corporation with PI3K (phosphatidylinositol-3,4,5-triphosphate)/Akt/mTOR (mammalian target of rapamycin) and Wnt pathway. The role of PI3K-Akt-mTOR and Wnt pathways in regulation of the cell cycle progression in cancer cell has been proposed (Figure 1). The activation of insulin/insulin-like growth factor (IGF) receptor by nutrients/growth factors activates PI3K-Akt pathway. The phosphorylated Akt activates mammalian target of rapamycin complex 1 (mTORC1), and the activated mTORC1 upregulates the protein synthesis but inhibits autophagy. Inhibition of autophagy rescues Dvl (Dish homolog in mammalian), and this leads to activation of Wnt pathway. Wnt pathway is the key pathway in activation of cell cycle, and the activated Wnt pathway upregulates the CyclinD; the c-Myc; the matrix metalloproteinases, COX-2, peroxisome proliferator-activated receptors (PPARs); and the growth factors and their receptors and downregulates E-cadherin, the cell cycle inhibitor p16INK4a (ARF), and p53 [30]. Wnt pathway thus regulates the cancer cell entry into the cell cycle through the production of CyclinD. CyclinD complexes with cyclin-dependent kinase 4/6 (Cdk4/6), inactivates the tumor suppressor protein retinoblastoma (Rb), and promotes the entry of the cell from G0 to G1 phase of cell cycle as well as metabolic reprogramming through the c-Myc activation as described above. In this context, c-Myc is acknowledged to play an important role to activate genes involved in predominantly cell cycle regulation, cellular metabolism, and protein synthesis, especially specific to G0-G-S transition as well as glycolysis and Krebs cycle, chromatin structure, and its transcriptional networks in cancer cells and embryonic stem cells as well [31, 32]. Given its crucial role in cancer progression and maintenance, c-Myc has been the ideal target for cancer therapy, and c-Myc targeting strategy in cancer therapy has been investigated in various means such as direct inhibition by antisense oligonucleotide [33] and siRNA [34], indirect inhibition by blocking transcription with BET bromodomain inhibitors such as JQ-1 [35], and blocking mRNA translation with mTOR inhibitor [36]. After a long time struggling on targeting c-Myc in cancer therapy, we are now witnessing a renewed interest in making Myc inhibition for the future cancer therapy. In the aspect of c-Myc contribution to the metabolism, c-Myc promotes a Warburg-like glycolytic phenotype through dual mechanism of upregulation of key glycolytic enzymes as described above, and suppression of peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) by direct inhibition through binding to its promoter [17]. PGC-1α is crucial for the anti-oxidative capacity and mitochondrial metabolism in cancer [37, 38] and contributes to the maintenance of CSC’s phenotype of self-renewal through controlling intracellular ROS levels. Myc/PGC-1α balance controls the metabolic phenotype of cancer cells as c-Myc dominance shifts to Warburg phenotype of differentiated cancer cells and PGC-1α dominance shifts to OXPHOS-dependent phenotype of CSCs [17]. Therefore, combining OXPHOS inhibition with c-Myc inhibition could provide a new multimodal approach for targeting the distinct metabolic features in cancer therapy.

Figure 1.

c-Myc contributes to the cell cycle regulation in corporation with PI3K/Akt/mTOR and Wnt pathway. The activation of insulin/IGF receptor by nutrients/growth factors activates PI3K-Akt pathway. The phosphorylated Akt activates mTORC1, which eventually leads to activation of Wnt pathway. Wnt pathway is the key pathway in activation of cell cycle, and the activated Wnt pathway upregulates the CyclinD, the c-Myc which would be involved in tumor initiation as well as tumor progression.


3. Cancer stem cell metabolism: a potential therapeutic target

CSCs also known as tumor-initiating cells (TICs) are a rare population of tumor cells with stem cell properties, which are thought to generate the tumor bulk and considered to drive the malignant growth, treatment resistance, minimal residual disease, and metastases. Along with the role of cancer drivers, CSCs also exhibit stem cell properties such as self-renewal and multilineage differentiation capacity [39]. CSCs are considered to be resistant to chemotherapy or radiations, both of which successfully destroy differentiated non stem-like cancer cells. As a matter of fact, even though current conventional anticancer therapies could achieve a transient control over the disease, a large number of patients experience tumor relapse or metastatic dissemination after an initial treatment with apparent disease-free period. Since CSCs, resisting to conventional therapies, attributes these biological behaviors, eradication of CSCs could be a promising target to totally exterminate the disease of cancer [40].

Although much is known regarding metabolic pathways important for cancer cell survival, the potential for therapeutic metabolic alteration of CSCs has not been fully uncovered [41], but recent studies indicate that metabolism and stemness are highly intertwined processes in tumor tissues, and CSCs possibly have different metabolic properties compared to non-CSCs.

Glucose homeostasis is reciprocally controlled by the catabolic glycolysis/OXPHOS and by the anabolic gluconeogenesis pathway. In the catabolic reaction, when oxygen is absent, glycolysis predominantly controls the metabolism of ATP production, while in the presence of oxygen, OXPHOS predominantly regulates the maximal ATP production in the mitochondria. Cancer cells preferentially metabolize glucose rather than OXPHOS even in the presence of oxygen defined as Warburg effect/aerobic glycolysis by the activation of some key genes such as c-Myc. In contrast to the somatic cells which primarily utilize OXPHOS, pluripotent stem cells including embryonal stem cells and induced pluripotent stem cells rely on glycolysis [42]. Therefore, it has to be pointed out that the biological functions of CSCs are different from those of differentiated cancer cells, making their phenotype more similar to normal stem cell, and metabolism is not the exception. Since aerobic glycolysis/Warburg effect has been widely accepted and recognized as a peculiar hallmark of cancer cells, it may be reasonable to expect that, conversely, CSC metabolism is mostly oriented toward mitochondrial OXPHOS. Actually, it is broadly accepted that ATP production in CSCs depends on glycolysis or OXPHOS in a tumor-type-dependent manner. The heterogeneity and plasticity of CSCs probably determine their primary source of energy to survive. The recent investigation has suggested that CSCs may display a broader repertoire of biochemical behavior in response to different environmental conditions, and accumulating evidence has indicated that CSCs utilize OXPHOS not only relying on the glycolysis [41, 43]. CSC metabolism show a highly plastic profile which allows to fulfill the energy requirements, according to the most suitable environmental condition. This metabolic flexibility of CSCs has been shown in diverse tumor types demonstrating that CSCs efficiently gain energy production from glycolysis when OXPHOS is blocked [44]. Recently, De Francesco et al. proposed the “two metabolic hit strategies” for eradication of CSCs (Figure 2) [45]. They demonstrated that the prolonged treatment with a mitochondria-interfering agent like doxycycline drastically impairs oxygen consumption rate (OCR) and mitochondrial respiration in MCF7 breast cancer cells. Such impairment in mitochondrial activity represents a first metabolic hit that constrains cellular metabolism of the surviving cancer cell subpopulation toward a predominantly glycolytic phenotype, resulting in metabolic inflexibility, as evidenced by the increased extracellular acidification rate (ECAR). In this sequence, the glycolysis inhibitor potentially acts a second metabolic hit which effectively targets CSCs. Thus, specific metabolic-oriented pharmacological intervention could reverse CSC metabolic plasticity toward an inflexible biochemical phenotype, representing a new synthetic-lethal metabolic strategy for eradicating CSCs.

Figure 2.

The treatment with a mitochondria-interfering agent impairs oxygen consumption rate (OCR) and mitochondrial respiration in cancer cells as a metabolic first hit that constrains cellular metabolism of the surviving cancer cell subpopulation toward a predominantly glycolytic phenotype, resulting in metabolic inflexibility, as evidenced by the increased extracellular acidification rate (ECAR). The use of a glycolysis inhibitor may therefore act as the second metabolic hit that efficiently targets CSCs by halting their biochemical machinery (X axis, time (min); Y axis, pmoles/min/mg protein; red line, mitochondria inhibitor treatment; blue line, control).


4. Targeting mitochondrial physiology in cancer stem cells

Mitochondria are key organelles involved in several processes related to cell proliferation and survival, and their most important function is the generation of ATP which holds cell metabolism. As the main energy producers, mitochondria produce ATP using tricarboxylic acid (TCA) cycle and OXPHOS. They also generate reactive oxygen species (ROS) during this process, which are sometimes harmful to the cells when produced excessively.

Because mitochondria play a key role in the alteration of oxidative stress and energy status, their functional characteristics have been considered to verify stemness like stem cell stability and pluripotency [46, 47]. Mitochondrial metabolic activity and antioxidant enzyme expression have shown to be closely related to the cell differentiation [48, 49]. Thus, we could assume that stem cell mitochondria play important roles in maintaining stemness and differentiation. However, whether the roles of CSC mitochondria are similar to stem cell mitochondria or so-called differentiated cancer cells in general is not clear. Based on the previous reports, the CSCs might be more differentiated than normal stem cells, and the mitochondrial properties of CSCs are possibly different from those of stem cells or general cancer cells [39, 50].

Mitochondria have a multi-level network of antioxidant and OXPHOS systems (Figure 3). Mitochondrial redox balances are regulated by the mitochondrial inner membrane electrochemical gradient. As shown in Figure 3, nicotinamide adenine dinucleotide (NADH) from TCA cycle is oxidized by Complex I in the electron transport chain (ETC) of OXPHOS. Electrons from Complex I and II are transferred to coenzyme Q10 and then passed on to Complex III, cytochrome c, Complex IV, and finally O2 to generate H2O. Complex V (ATP synthase; F0-F1) generates ATP from ADP as well as inorganic phosphate Pi.

Figure 3.

Mitochondrial redox balances are regulated by the mitochondrial inner membrane electrochemical gradient. NADH from TCA cycle is oxidized by Complex I in the ETC. Electrons from Complex I and II are transferred to coenzyme Q10 and then passed on to Complex III, cytochrome c, Complex IV, and finally O2 to generate H2O. Complex V (F0F1-ATP synthase) generates ATP from ADP for the cellular energy source.

A powerful strategy focused on mitochondrial biogenetics as a target to eradicate CSCs involves inhibition of the ETC complex, with consequent ROS overproduction. Dong et al. demonstrated that the suppression of mitochondrial Complex I activity inhibited oxygen consumption and induced glycolysis in breast CSCs as a result of loss of fructose-1,6-biphosphatase implying that overproduction of ROS and reduction in glucose metabolism might be effective against breast CSCs [11]. Hirsch et al. also showed that metformin, the first-line antidiabetic drug, selectively killed the CSCs in breast cancer cell line through the inhibition of Complex I [51]. Furthermore, atovaquone, an FDA-approved antimalarial drug, inhibits the propagation of breast cancer cell line MCF7-derived CSCs through the selective OXPHOS inhibition by targeting the CoQ10 dependence of mitochondrial Complex III [52]. This has been explored in the context of therapy as indicated by Alvero et al. using the novel isoflavone derivative NV-128 which significantly decreased mitochondrial function, as shown by a decrease in ATP, Complex I and Complex IV levels, and induced cell death in ovarian CSCs [53]. Finally, mitochondria-targeted vitamin E succinate (MitoVES) has been well characterized as an agent, which potentiates the ability to induce apoptosis in breast CSCs [54]. Reduction of mitochondrial membrane potential, overproduction of mitochondrial ROS, and inhibition of mitochondrial biogenesis have been demonstrated to affect CSC proliferation and survival [55]. These inputs indicate that the maintenance of CSC proliferation may not only be dependent on glycolysis, but is also based on mitochondrial activity. Therefore, the specific mitochondrial-targeted compounds which induce cell death in chemoresistant CSCs are promising novel therapeutic venue to treat cancer patients with relapsed or metastatic diseases. The most important point is that mitochondria from CSCs are not indistinguishable to those from differentiated non stem-like tumor cells in divergent aspects. Since CSCs are considered to be heterogeneous and adaptive metabolic profiles, the future therapy targeting cellular metabolism should be designed in a form of simultaneous or selective blockade of both glycolysis and mitochondrial respiration to completely eradicate CSCs [20]. Consequently, dual inhibition of glycolytic and mitochondrial energy pathways has proven to be effective against tumor growth in a number of preclinical cancer models. For instance, dual inhibition of glycolysis by 2-deoxyglucose (2-DG) and OXPHOS by metformin is effective in vivo against breast cancer cell xenograft model [56]. However, hexokinase inhibitors such as 2-DG and 3-bromopyruvate have been unfortunately discontinued in clinical trials. There has been an elegant study demonstrating sarcoma cells to be more sensitive than normal cells to dual inhibition of glycolysis with 2-deoxyglucose and OXPHOS with oligomycin or metformin [57]. Recently, Kang et al. have demonstrated that ALDH inhibitor gossypol combined with mitochondrial Complex I inhibitor phenformin resulted in up to 80% ATP depletion in non-small cell lung cancer, which induced significant tumor regression in the cancer xenograft model [58]. These warrant that a key molecule regulating cancer energy metabolism can be a therapeutic target.

Meanwhile, other mitochondria-related processes like activation of developmental signaling pathways including Hedgehog, Notch, and Wnt are also the druggable targets; the drug targeting Notch and Hedgehog pathway has been developed [59], and numerous molecules acting on mitochondria has been used or being tested in clinical trials [60]. Adding these attempts targeting mitochondria, we will emphasize that the dual inhibition of metabolic pathways could be an approach with greater potential to eradicate heterogeneous CSCs rather than singularly targeting glycolysis or OXPHOS pathway.


5. Novel approach to target cellular metabolism in osteosarcoma

Osteosarcoma and mitochondria have been investigated since 1970; however, those are mostly limited to the morphological characteristics by microscopic or electron microscopic observation [61, 62].

Giang et al. demonstrated that highly invasive and metastatic cell lines were more relied on Warburg effect-like glycolysis than their parental cell lines which showed similar mitochondrial oxygen consumption rate to fetal osteoblasts, suggesting that highly metastatic and invasive cell lines were in the state of suppression of mitochondrial function and upregulation of glycolysis. They suggested that the mechanism of mitochondrial dysfunction was the results of mitochondrial permeability transition such as mitochondrial swelling, depolarization, and membrane permeabilization, and they also demonstrated that this mitochondrial dysfunction and the Warburg effect are reversed by the treatment with mitochondrial permeability transition inhibitor sanglifehrin A [63]. These results indicated that osteosarcoma cells might possess the metabolic plasticity in response to their microenvironment especially hypoxia-reoxygenation caused by an irregular blood supply within tumors, an immature and leaky vasculature, and an abnormal and constantly changing vessel network architecture.

Another biochemical mechanism which contributes to the glycolytic rate of tumor cells is the inhibition of mitochondrial ATP synthase (F1F0-ATPase) by the natural inhibitor protein IF1 [64]. Barbato et al. reported that IF1 modulates the mitochondrial membrane potential and oxidative phosphorylation rate in osteosarcoma cells suggesting that interaction between IF1 and FoF1-ATPase might regulate the OXPHOS and glycolysis [65]. However, the detailed mechanisms regulating the cellular bioenergetics by IF1 have been still controversial in cancer cells under the complex microenvironment.

Recently, novel strategy targeting CSCs through phytochemicals and their analogs has been proposed, and mitochondria are one of their potential targets [66]. Among the various compounds, pterostilbene (PTE), which is a methylated resveratrol derived from plants, has been shown to inhibit CSC properties in breast cancer [67, 68], glioma [69], hepatocellular carcinoma [70], and lung cancer [71] through the inhibition of multiple pathways which are possibly related to the CSC propagation such as Wnt, Hedgehog, Notch, and PI3K/Akt. Honokiol (HNK), which is the extract from Magnolia obovata, has shown its various antitumor effects through the inhibition of several pathways such as PI3K/Akt/mTOR, Wnt, and c-Myc [72, 73, 74]. Besides these effects of PTE and HNK, we have identified that PTE in combination with HNK could be the possible metabolism-targeted therapy against osteosarcoma as a “two hit” or “dual inhibition” of metabolic pathways, OXPHOS and glycolysis. PTE treatment on human osteosarcoma cell lines SaOS2, U2OS, and MG63 reduced viabilities of all cell lines in dose-dependent manner, and expression of stem cell marker such as Oct3, NS, and CD44 and the ability of sphere formation were also decreased in terms of sphere number and size (Figure 4a). PTE reduced the activity of F0F1-ATP synthase, Complex V predominantly (Figure 4b), and the mitochondrial oxygen consumption rates and synthetic amount of ATP were also decreased in spheroid condition (Figure 4c). These results suggest that PTE possibly targets stem cell population which preferably relies on OXPHOS, suppressing ATP synthesis via F0F1-ATP synthase inhibition as well as increased ROS production in osteosarcoma cells, and changes metabolic flax to glycolysis-dependent feature.

Figure 4.

(a) Pterostilbene (PTE) treatment on human osteosarcoma cells reduced the ability of sphere formation in terms of sphere number and size. (b) PTE reduced the activity of F0F1-ATP synthase, Complex V. (c) The mitochondrial OCR rates and synthetic amount of ATP were also decreased in spheroid condition (Kishi et al. unpublished data).

As aforementioned before, c-Myc promotes a Warburg-like glycolytic phenotype through the upregulation of key glycolytic enzymes along with the suppression of PGC-1α. There are several reports regarding the anticancer activity of HNK which is possibly associated with c-Myc as well as JQ1, a BET bromodomain inhibitor [74]. Thus, we conducted dual inhibition of OXPHOS by PTE and c-Myc inhibition by HNK or JQ1. The results showed that both of these agents synergistically inhibited osteosarcoma cell growth in a dose-dependent manner (Figure 5). Now, we are conducting an investigation of dual metabolic inhibition via in vivo experiments using our own established rat osteosarcoma model.

Figure 5.

Dual inhibition of OXPHOS by PTE and c-Myc inhibition by Honokiol (HNK) or JQ1 showed the synergistic effect on inhibition of osteosarcoma cell growth in a dose-dependent manner (Kishi et al. unpublished data).

The above results suggested that c-Myc inhibitor could lead to metabolic flux to OXPHOS and PTE could lead to metabolic flux to glycolysis. Thus, these exerted a great synergistic effect with “two metabolic hits” or “dual metabolic inhibition” of distinct metabolic features, OXPHOS and glycolysis, and it could be a novel therapeutic strategy against osteosarcoma, possibly targeting both stemlike cell population and general tumor cell population.


6. Conclusions

Prognosis of the patients with osteosarcoma has been improved; actually, we could say “dramatically,” over the last quarter-century. However, it is also true that it has reached to plateau without any breakthroughs, and nearly 30% of patients still have to face very severe poor prognosis, especially with metastatic disease. We need to develop a novel treatment to combat such a poor prognostic situation. Targeting the distinct metabolic features of OXPHOS and glycolysis with the concept of “two metabolic hits”/“dual metabolic inhibition” strategy could bring a new insight into the field of osteosarcoma treatment, and some natural compounds such as pterostilbene and honokiol could be the possible candidates to achieve this aim.



This article is supported by a part of the Grant to KH (No. 15K10455 from the Ministry of Sports, Culture, Education, Science and Technology, Japan).


Conflict of interest

All authors have no “conflict of interest” to be declared.


  1. 1. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nature Medicine. 1997;3:730-737
  2. 2. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proceedings of the National Academy of Sciences of the United States of America. 2003;100:3983-3988
  3. 3. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, et al. Identification of human brain tumour initiating cells. Nature. 2004;432:396-401
  4. 4. Gibbs CP, Kukekov VG, Reith JD, Tchigrinova O, Suslov ON, Scott EW, et al. Stem-like cells in bone sarcomas: Implications for tumorigenesis. Neoplasia. 2005;7:967-976
  5. 5. Fujii H, Honoki K, Tsujiuchi T, Kido A, Yoshitani K, Takakura Y. Sphere-forming stem-like cell populations with drug resistance in human sarcoma cell lines. International Journal of Oncology. 2009;34:1381-1386
  6. 6. Honoki K, Fujii H, Kubo A, Kido A, Mori T, Tanaka Y, et al. Possible involvement of stem-like populations with elevated ALDH1 in sarcomas for chemotherapeutic drug resistance. Oncology Reports. 2010;24:501-505
  7. 7. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, et al. Identification of pancreatic cancer stem cells. Cancer Research. 2007;67:1030-1037
  8. 8. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell. 2007;1:313-323
  9. 9. Lonardo E, Hermann PC, Mueller MT, Huber S, Balic A, Miranda-Lorenzo I, et al. Nodal/activin signaling drives self-renewal and tumorigenicity of pancreatic cancer stem cells and provides a target for combined drug therapy. Cell Stem Cell. 2011;9:433-446
  10. 10. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science. 2009;324:1029-1033
  11. 11. Dong C, Yuan T, Wu Y, Wang Y, Fan TW, Miriyala S, et al. Loss of FBP1 by snail-mediated repression provides metabolic advantages in basal-like breast cancer. Cancer Cell. 2013;23:316-331
  12. 12. Li F, Wang Y, Zeller KI, Potter JJ, Wonsey DR, O’Donnell KA, et al. Myc stimulates nuclearly encoded mitochondrial genes and mitochondrial biogenesis. Molecular and Cellular Biology. 2005;25:6225-6234
  13. 13. Folmes CD, Dzeja PP, Nelson TJ, Terzic A. Metabolic plasticity in stem cell homeostasis and differentiation. Cell Stem Cell. 2012;11:596-606
  14. 14. Shen YA, Wang CY, Hsieh YT, Chen YJ, Wei YH. Metabolic reprogramming orchestrates cancer stem cell properties in nasopharyngeal carcinoma. Cell Cycle. 2015;14:86-98
  15. 15. Ye XQ , Li Q , Wang GH, Sun FF, Huang GJ, Bian XW, et al. Mitochondrial and energy metabolism-related properties as novel indicators of lung cancer stem cells. International Journal of Cancer. 2011;129:820-831
  16. 16. Janiszewska M, Suvà ML, Riggi N, Houtkooper RH, Auwerx J, Clément-Schatlo V, et al. Imp2 controls oxidative phosphorylation and is crucial for preserving glioblastoma cancer stem cells. Genes & Development. 2012;26:1926-1944
  17. 17. Sancho P, Burgos-Ramos E, Tavera A, Bou Kheir T, Jagust P, Schoenhals M, et al. MYC/PGC-1α balance determines the metabolic phenotype and plasticity of pancreatic cancer stem cells. Cell Metabolism. 2015;22:590-605
  18. 18. Palorini R, Votta G, Balestrieri C, Monestiroli A, Olivieri S, Vento R, et al. Energy metabolism characterization of a novel cancer stem cell-like line 3AB-OS. Journal of Cellular Biochemistry. 2014;115:368-379
  19. 19. Funes JM, Quintero M, Henderson S, Martinez D, Qureshi U, Westwood C, et al. Transformation of human mesenchymal stem cells increases their dependency on oxidative phosphorylation for energy production. Proceedings of the National Academy of Sciences of the United States of America. 2007;104:6223-6228
  20. 20. Peiris-Pagès M, Martinez-Outschoorn UE, Pestell RG, Sotgia F, Lisanti MP. Cancer stem cell metabolism. Breast Cancer Research. 2016;18:55. DOI: 10.1186/s13058-016-0712-6
  21. 21. Bomken S, Fišer K, Heidenreich O, Vormoor J. Understanding the cancer stem cell. British Journal of Cancer. 2010;103:439-445
  22. 22. Bonuccelli G, Avnet S, Grisendi G, Salerno M, Granchi D, Dominici M, et al. Role of mesenchymal stem cells in osteosarcoma and metabolic reprogramming of tumor cells. Oncotarget. 2014;5:7575-7588
  23. 23. Moore KA, Lemischka IR. Stem cells and their niches. Science. 2006;311:1880-1885
  24. 24. Lamb R, Harrison H, Hulit J, Smith DL, Lisanti MP, Sotgia F. Mitochondria as new therapeutic targets for eradicating cancer stem cells: Quantitative proteomics and functional validation via MCT1/2 inhibition. Oncotarget. 2014;5:11029-11037
  25. 25. Lamb R, Ozsvari B, Lisanti CL, Tanowitz HB, Howell A, Martinez-Outschoorn UE, et al. Antibiotics that target mitochondria effectively eradicate cancer stem cells, across multiple tumor types: Treating cancer like an infectious disease. Oncotarget. 2015;6:4569-4584
  26. 26. Dang CV, Le A, Gao P. MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clinical Cancer Research. 2009;15:6479-6483
  27. 27. Kim JW, Gao P, Liu YC, Semenza GL, Dang CV. Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1. Molecular and Cellular Biology. 2007;27:7381-7393
  28. 28. Osthus RC, Shim H, Kim S, Li Q , Reddy R, Mukherjee M, et al. Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc. The Journal of Biological Chemistry. 2000;275:21797-21800
  29. 29. Le A et al. Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proceedings of the National Academy of Sciences of the United States of America. 2010;107:2037
  30. 30. Available from:; 2010
  31. 31. Kim J, Woo AJ, Chu J, Snow JW, Fujiwara Y, Kim CG, et al. A myc network accounts for similarities between embryonic stem and cancer cell transcription programs. Cell. 2010;143:313-324
  32. 32. Lin CY, Loven J, Rahl PB, Paranal RM, Burge CB, Bradner JE, et al. Transcriptional amplification in tumor cells with elevated C-Myc. Cell. 2012;151:56-67
  33. 33. Devi GR, Beer TM, Corless CL, Arora V, Weller DL, Iversen PL. In vivo bioavailability and pharmacokinetics of a c-MYC antisense phosphorodiamidate morpholino oligomer, AVI-4126, in solid tumors. Clinical Cancer Research. 2005;11:3930-3938
  34. 34. Wang H, Mannava S, Grachtchouk V, Zhuang D, Soengas MS, Gudkov AV, et al. c-Myc depletion inhibits proliferation of human tumor cells at various stages of the cell cycle. Oncogene. 2008;27:1905-1915
  35. 35. Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 2011;146:904-917
  36. 36. Wiegering A, Uthe FW, Jamieson T, Ruoss Y, Hüttenrauch M, Küspert M, et al. Targeting translation initiation bypasses signaling crosstalk mechanisms that maintain high myc levels in colorectal cancer. Cancer Discovery. 2015;5:768-781
  37. 37. Vazquez F, Lim JH, Chim H, Bhalla K, Girnun G, Pierce K, et al. PGC1α expression defines a subset of human melanoma tumors with increased mitochondrial capacity and resistance to oxidative stress. Cancer Cell. 2013;23:287-301
  38. 38. LeBleu VS, O’Connell JT, Gonzalez Herrera KN, Wikman H, Pantel K, Haigis MC, et al. PGC-1α mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis. Nature Cell Biology. 2014;16:992-1003. 1-15
  39. 39. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414:105-111. DOI: 10.1038/35102167
  40. 40. Chen K, Huang YH, Jl C. Understanding and targeting cancer stem cells: Therapeutic implications and challenges. Acta Pharmacologica Sinica. 2013;34:732-740. DOI: 10.1038/aps.2013.27
  41. 41. Sancho P, Barneda D, Heeschen C. Hallmarks of cancer stem cell metabolism. British Journal of Cancer. 2016;114:1305-1312. DOI: 10.1038/bjc.2016.152
  42. 42. Facucho-Oliveira JM, St John JC. The relationship between pluripotency and mitochondrial DNA proliferation during early embryo development and embryonic stem cell differentiation. Stem Cell Reviews. 2009;5:140-158. DOI: 10.1007/s12015-009-9058-0
  43. 43. Martinez-Outschoorn UE, Peiris-Pagés M, Pestell RG, Sotgia F, Lisanti MP. Cancer metabolism: A therapeutic perspective. Nature Reviews. Clinical Oncology. 2017;14:113. DOI: 10.1038/nrclinonc.2017.1
  44. 44. Vlashi E, Lagadec C, Vergnes L, Matsutani T, Masui K, Poulou M, et al. Metabolic state of glioma stem cells and nontumorigenic cells. Proceedings of the National Academy of Sciences of the United States of America. 2011;108:16062-16067. DOI: 10.1073/pnas.1106704108
  45. 45. De Francesco EM, Bonuccelli G, Maggiolini M, Sotgia F, Lisanti MP. Vitamin C and doxycycline: A synthetic lethal combination therapy targeting metabolic flexibility in cancer stem cells (CSCs). Oncotarget. 2017;8:67269-67286. DOI: 10.18632/oncotarget.18428
  46. 46. Lonergan T, Brenner C, Bavister B. Differentiation-related changes in mitochondrial properties as indicators of stem cell competence. Journal of Cellular Physiology. 2006;208:149-153
  47. 47. Bavister BD. The mitochondrial contribution to stem cell biology. Reproduction, Fertility, and Development. 2006;18:829-838
  48. 48. Sauer H, Wartenberg M. Reactive oxygen species as signaling molecules in cardiovascular differentiation of embryonic stem cells and tumor-induced angiogenesis. Antioxidants & Redox Signaling. 2005;7:1423-1434
  49. 49. Plotnikov EY, Marei MV, Podgornyi OV, Aleksandrova MA, Zorov DB, Sukhikh GT. Functional activity of mitochondria in cultured neural precursor cells. Bulletin of Experimental Biology and Medicine. 2006;141:142-146
  50. 50. Kucia M, Ratajczak MZ. Stem cells as a two edged sword—From regeneration to tumor formation. Journal of Physiology and Pharmacology. 2006;57(Suppl 7):5-16
  51. 51. Hirsch HA, Iliopoulos D, Struhl K. Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth. Proceedings of the National Academy of Sciences of the United States of America. 2013;110:972-977. DOI: 10.1073/pnas.1221055110
  52. 52. Fiorillo M, Lamb R, Tanowitz HB, Mutti L, Krstic-Demonacos M, Cappello AR, et al. Repurposing atovaquone: Targeting mitochondrial complex III and OXPHOS to eradicate cancer stem cells. Oncotarget. 2016;7:34084-34099. DOI: 10.18632/oncotarget.9122
  53. 53. Alvero AB, Montagna MK, Holmberg JC, Craveiro V, Brown D, Mor G. Targeting the mitochondria activates two independent cell death pathways in ovarian cancer stem cells. Molecular Cancer Therapeutics. 2011;10:1385-1393. DOI: 10.1158/1535-7163.MCT-11-0023
  54. 54. Biasutto L, Dong LF, Zoratti M, Neuzil J. Mitochondrially targeted anti-cancer agents. Mitochondrion. 2010;10:670-681. DOI: 10.1016/j.mito.2010.06.004
  55. 55. Fulda S, Galluzzi L, Kroemer G. Targeting mitochondria for cancer therapy. Nature Reviews. Drug Discovery. 2010;9:447-464. DOI: 10.1038/nrd3137
  56. 56. Cheong JH, Park ES, Liang J, Dennison JB, Tsavachidou D, Nguyen-Charles C, et al. Dual inhibition of tumor energy pathway by 2-deoxyglucose and metformin is effective against a broad spectrum of preclinical cancer models. Molecular Cancer Therapeutics. 2011;10:2350-2362. DOI: 10.1158/1535-7163.MCT-11-0497
  57. 57. Issaq SH, Teicher BA, Monks A. Bioenergetic properties of human sarcoma cells help define sensitivity to metabolic inhibitors. Cell Cycle. 2014;13:1152-1161. DOI: 10.4161/cc.28010
  58. 58. Kang JH, Lee SH, Lee JS, Nam B, Seong TW, Son J, et al. Aldehyde dehydrogenase inhibition combined with phenformin treatment reversed NSCLC through ATP depletion. Oncotarget. 2016;7:49397-49410
  59. 59. Loureiro R, Mesquita KA, Oliveira PJ, Vega-Naredo I. Mitochondria in cancer stem cells: A target for therapy. Recent Patents on Endocrine, Metabolic & Immune Drug Discovery. 2013;7:102-114
  60. 60. Pathania D, Millard M, Neamati N. Opportunities in discovery and delivery of anticancer drugs targeting mitochondria and cancer cell metabolism. Advanced Drug Delivery Reviews. 2009;61:1250-1275. DOI: 10.1016/j.addr.2009.05.010
  61. 61. Ghadially FN, Mehta PN. Ultrastructure of osteogenic sarcoma. Cancer. 1970;25:1457-1467
  62. 62. Singh I, Tsang KY, Ludwig GD. Alterations in the mitochondria of human osteosarcoma cells with glucocorticoids. Cancer Research. 1974;34:2946-2952
  63. 63. Giang AH, Raymond T, Brookes P, de Mesy Bentley K, Schwarz E, O’Keefe R, et al. Mitochondrial dysfunction and permeability transition in osteosarcoma cells showing the Warburg effect. The Journal of Biological Chemistry. 2013;288:33303-33311. DOI: 10.1074/jbc.M113.507129
  64. 64. Sánchez-Cenizo L, Formentini L, Aldea M, Ortega AD, García-Huerta P, Sánchez-Aragó M, et al. Up-regulation of the ATPase inhibitory factor 1 (IF1) of the mitochondrial H+-ATP synthase in human tumors mediates the metabolic shift of cancer cells to a Warburg phenotype. The Journal of Biological Chemistry. 2010;285:25308-25313. DOI: 10.1074/jbc.M110.146480
  65. 65. Barbato S, Sgarbi G, Gorini G, Baracca A, Solaini G. The inhibitor protein (IF1) of the F1F0-ATPase modulates human osteosarcoma cell bioenergetics. The Journal of Biological Chemistry. 2015;290:6338-6348. DOI: 10.1074/jbc.M114.631788
  66. 66. Dandawate P, Padhye S, Ahmad A, Sarkar FH. Novel strategies targeting cancer stem cells through phytochemicals and their analogs. Drug Delivery and Translational Research. 2013;3:165-182. DOI: 10.1007/s13346-012-0079-x
  67. 67. Singh AK, Sharma N, Ghosh M, Park YH, Jeong DK. Emerging importance of dietary phytochemicals in fight against cancer: Role in targeting cancer stem cells. Critical Reviews in Food Science and Nutrition. 2017;57:3449-3463. DOI: 10.1080/10408398.2015.1129310
  68. 68. Mak KK, Wu AT, Lee WH, Chang TC, Chiou JF, Wang LS, et al. Pterostilbene, a bioactive component of blueberries, suppresses the generation of breast cancer stem cells within tumor microenvironment and metastasis via modulating NF-κB/microRNA 448 circuit. Molecular Nutrition & Food Research. 2013;57:1123-1134. DOI: 10.1002/mnfr.201200549
  69. 69. Huynh TT, Lin CM, Lee WH, Wu AT, Lin YK, Lin YF, et al. Pterostilbene suppressed irradiation-resistant glioma stem cells by modulating GRP78/miR-205 axis. Journal of Nutritional Biochemistry. 2015;26:466-475. DOI: 10.1016/j.jnutbio.2014.11.015
  70. 70. Lee CM, Su YH, Huynh TT, Lee WH, Chiou JF, Lin YK, et al. Blueberry isolate, pterostilbene, functions as a potential anticancer stem cell agent in suppressing irradiation-mediated enrichment of hepatoma stem cells. Evidence-Based Complementary and Alternative Medicine. 2013;2013:258425. DOI: 10.1155/2013/258425
  71. 71. Huang WC, Chan ML, Chen MJ, Tsai TH, Chen YJ. Modulation of macrophage polarization and lung cancer cell stemness by MUC1 and development of a related small-molecule inhibitor pterostilbene. Oncotarget. 2016;7:39363-39375. DOI: 10.18632/oncotarget.8101
  72. 72. Li Z, Dong H, Li M, Wu Y, Liu Y, Zhao Y, et al. Honokiol induces autophagy and apoptosis of osteosarcoma through PI3K/Akt/mTOR signaling pathway. Molecular Medicine Reports. 2018;17:2719-2723. DOI: 10.3892/mmr.2017.8123
  73. 73. Yao CJ, Lai GM, Yeh CT, Lai MT, Shih PH, Chao WJ, et al. Honokiol eliminates human oral cancer stem-like cells accompanied with suppression of Wnt/β-catenin signaling and apoptosis induction. Evidence-based Complementary and Alternative Medicine. 2013;2013:146136. DOI: 10.1155/2013/146136
  74. 74. Hahm ER, Singh KB, Singh SV. c-Myc is a novel target of cell cycle arrest by honokiol in prostate cancer cells. Cell Cycle. 2016;15(17):2309-2320. DOI: 10.1080/15384101.2016.1201253

Written By

Shingo Kishi, Kanya Honoki, Yasuhito Tanaka and Hiroki Kuniyasu

Submitted: 21 August 2018 Reviewed: 20 November 2018 Published: 15 March 2019